Cara Therapeutics, Inc. Enters Into Development and Commercial Alliance With Maruishi for Novel Kappa Opioid Agonist , CR845, in Japan
4/29/2013 10:01:22 AM
More...
|
Cara Therapeutics, Inc. Reports Positive Results from Phase II Trial of Novel Peripheral Kappa Agonist, CR845, in Acute Post-Operative Pain
6/11/2012 6:47:56 AM
More...
|
Cara Therapeutics, Inc. Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
5/3/2012 11:21:29 AM
More...
|
Cara Therapeutics, Inc. Successfully Completes Phase I Study With Oral Formulation of its Novel Kappa Opioid Receptor Agonist, CR845
4/3/2012 10:40:55 AM
More...
|
Cara Therapeutics, Inc. Initiates Phase I Study with Oral Formulation of Novel Peripherally-Acting Kappa Opioid Agonist
11/22/2011 10:47:04 AM
More...
|
Cara Therapeutics, Inc. Initiates Phase II Trial of Novel Analgesic in Acute Post-Operative Pain
8/3/2011 9:55:52 AM
More...
|
Unigene Laboratories, Inc. (UGNE) Announces Manufacturing and Clinical Supply Agreement with Cara Therapeutics, Inc. for Phase 1 Study of Novel Kappa Receptor Agonist
5/19/2011 10:27:25 AM
More...
|
Cara Therapeutics, Inc. Announces Appointment of James B. Jones, M.D., Pharm.D., as Chief Medical Officer
3/30/2011 6:33:00 AM
More...
|
Cara Therapeutics, Inc. Secures $15 Million Series D Financing to Continue Clinical Development of CR845
7/21/2010 6:39:02 AM
More...
|
Cara Therapeutics, Inc. Reports Positive Phase II Data for Novel Peripheral Analgesic in Acute Post-Operative Pain
2/8/2010 7:25:32 AM
More...
|
|